Common research peptide stack pairings and why
Research peptides are often studied as pairs or stacks rather than individually. The pairings are not arbitrary — they reflect either complementary mechanism (two compounds that act on the same axis at different points), structural similarity (a compound and its closest comparator), or historical research convention (pairings that emerged in foundational studies and remain useful for comparison). This article walks through the four most common research-stack pairings in the Nexus catalog and the mechanism logic behind each.
BPC-157 and TB-500 — tissue repair research
The pentadecapeptide BPC-157 and thymosin beta-4 acetate (TB-500) are the two most-studied research peptides in the tissue-repair category. The pairing is mechanism-complementary: BPC-157 research has examined nitric oxide pathway interaction, growth factor modulation (including VEGF and EGF), and FAK-paxillin signaling cascades involved in tissue remodeling; TB-500 research has examined actin sequestration, cell migration, and tissue-repair signaling at different molecular targets. The two compounds engage distinct pathways relevant to similar research questions, which makes them natural side-by-side research-stack candidates.
In the Nexus catalog, the pairing is supported by three pre-mixed blend formats — BPC-157 + TB-500 at 2mg+2mg, 5mg+5mg, and 10mg+10mg — for research applications where a single-vial format is preferred. Tri-peptide blends extend the pairing with GHK-Cu (a copper-binding tripeptide from the cosmetic category) and KPV (an alpha-MSH-derived tripeptide).
CJC-1295 and Ipamorelin — GHRH + GHRP pulsatile signaling
The growth-hormone-axis pairing of a GHRH analog (CJC-1295) with a GHRP / ghrelin-receptor agonist (ipamorelin) is the canonical research stack for studying pulsatile GH signaling. The mechanism logic: GHRH analogs prime the pituitary somatotropes for GH release by binding GHRH receptors; GHRPs trigger GH release by binding the growth hormone secretagogue receptor (ghrelin receptor). The two pathways converge on GH release but engage different receptors and signaling cascades. Studying them together separates the contribution of each from the combined effect.
The Nexus catalog supports the pairing at two pre-mixed dose ratios: CJC-1295 (No DAC) + ipamorelin at 5mg+5mg, and CJC-1295 (No DAC) + ipamorelin at 10mg+10mg. The "No DAC" choice in the blends is intentional — the short-acting CJC-1295 matches the short-acting ipamorelin pharmacokinetics for pulse-style research. For long-acting research, the CJC-1295 With DAC variant pairs with ipamorelin as a separate stack.
MOTS-c, humanin, NAD+ — mitochondrial bioenergetics research
Mitochondrial-derived peptide research is a younger field than tissue-repair or GH-axis research, but the within-family pairings have emerged quickly. MOTS-c and humanin are both mitochondrial open-reading-frame-derived peptides (humanin discovered in 2003, MOTS-c in 2015); they engage related but non-identical mitochondrial signaling pathways. NAD+ is not a peptide — it is a small-molecule cofactor central to mitochondrial bioenergetics — but research stacking NAD+ with MOTS-c or humanin is common because the pathways converge on mitochondrial function. SS-31 (elamipretide) extends the stack as a mitochondrial-targeted antioxidant peptide.
The Nexus catalog supports these pairings as standalone products in the Longevity & Cellular Health and Mitochondrial & Energy categories. Pre-mixed blends are not currently offered for the mitochondrial-peptide stacks; researchers typically prefer the dosing flexibility of standalone compounds for this research family.
The multi-agonist incretin family — semaglutide, tirzepatide, retatrutide
The incretin-pathway research family — semaglutide (GLP-1 single agonist), tirzepatide (GIP/GLP-1 dual agonist), retatrutide (GLP-1/GIP/glucagon triple agonist), mazdutide and survodutide (GLP-1/glucagon dual agonists), and cagrilintide (amylin analog) — is the largest contemporary research peptide family by published literature. The pairing logic is comparative pharmacology: each compound engages a different combination of incretin and amylin receptors, and studying them side-by-side isolates the contribution of each receptor target to the observed research effect.
In the Nexus catalog, the comparative-pharmacology research convention is supported by both standalone products (all six listed above) and pre-mixed blends pairing GLP-1 agonists with amylin analogs: cagri-sema (cagrilintide + semaglutide), and retatrutide + cagrilintide. The blends enable research on combined incretin-and-amylin pharmacology in a single-vial format.
Khavinson bioregulator family — tissue-axis pairings
The Khavinson research family (15 short tetrapeptide bioregulators in the Russian Bioregulators category) has its own internal-pairing convention organized around tissue axis rather than receptor. Bronchogen + chonluten for respiratory-axis research, cardiogen + vesugen for cardiovascular-axis research, epithalon + pinealon for pineal-axis research, thymalin + crystagen for thymic / immune research. The pairings are tissue-axis-based because the Khavinson framework is tissue-specific by design — each bioregulator is encoded with tissue-specific research focus through its sequence.
When NOT to stack
Stack research adds confounding variables. The first time a researcher works with a new compound, single-compound research provides cleaner data than stack research. Mechanism-of-action studies, dose-response curves, and binding-affinity measurements are usually cleaner with single-compound designs. Stack designs are most useful when the research question explicitly involves the combined effect — e.g., does combining a GHRH analog with a GHRP produce a different GH-release profile than either alone? — and the experimental design specifically isolates the combination effect.
Even within stack designs, separating the components into separate vials (rather than using a pre-mixed blend) allows independent variation of each component's dose, which is useful for ratio-dependent research questions. Pre-mixed blends are most useful when the research convention is fixed at a known dose ratio.